There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD73


CD73 Molecule Information

Target Synonym:CD73,5 -NT,NT5,NTE,Ecto-5 -nucleotidase,NT5E,5 -Nucleotidase Ecto,Ecto-5-Nucleotidase,5-NT,Purine 5-Prime-Nucleotidase,5-Nucleotidase, Ecto (CD73),5 Nucleotidase (CD73),5-Nucleotidase Ecto,5-Nucleotidase,CD73 Antigen,EC,CALJA,E5NT,ENT,NT,EN,EC:3.1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Phase 3 Clinical

CD73 Protein Product ListCompare or Buy

CD73 Part of Bioactivity data


Anti-CD73 antibody (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD73, His Tag (HPLC-verified) (Cat. No. CD3-H52H7) with an affinity constant of 0.164 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).


Loaded Anti-CD73 MAb (Human IgG1) on AHC Biosensor, can bind Human CD73, His Tag (HPLC-verified) (Cat. No. CD3-H52H7) with an affinity constant of 0.179 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD73 Molecule Synonym Name


CD73 Molecule Background

5'-nucleotidase (5'-NT), also known as ecto-5'-nucleotidase or CD73 (cluster of differentiation 73), is an enzyme that is encoded by the NT5E gene. CD73 commonly serves to convert AMP to adenosine. Ecto-5-prime-nucleotidase (5-prime-ribonucleotide phosphohydrolase) catalyzes the conversion at neutral pH of purine 5-prime mononucleotides to nucleosides, the preferred substrate being AMP. Other forms of 5-prime nucleotidase exist in the cytoplasm and lysosomes and can be distinguished from ecto-NT5 by their substrate affinities, requirement for divalent magnesium ion, activation by ATP, and inhibition by inorganic phosphate. Rare allelic variants are associated with a syndrome of adult-onset calcification of joints and arteries (CALJA) affecting the iliac, femoral, and tibial arteries reducing circulation in the legs and the joints of the hands and feet causing pain.

CD73 References

CD73 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CD73 monoclonal antibody (Bristol-Myers Squibb) Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
LY-3475070 LY-3475070 Phase 1 Clinical Eli Lilly And Company Neoplasms Details
BMS-986179 BMS-986179 Phase 2 Clinical Bristol-Myers Squibb Company Solid tumours Details
AB-680 AB-680 Phase 2 Clinical Arcus Biosciences Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms Details
Oleclumab MEDI-9447 Phase 2 Clinical Medimmune Llc Solid tumours; Ovarian Neoplasms; Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CPI-006 CPI-006 Phase 3 Clinical Corvus Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Urinary Bladder Neoplasms; Sarcoma; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
HLX-23 HLX-23 Phase 1 Clinical Shanghai Fuhong Henlius Biopharmaceutical Co Ltd Solid tumours Details
Uliledlimab TJ-004309; TJD-5; TJ-4309 Phase 2 Clinical I-Mab Biopharma Co Ltd Solid tumours; Neoplasm Metastasis Details
SRF-373 NZV-930; SRF-373 Phase 1 Clinical Surface Oncology Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.